A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
Conditions:   Gastrointestinal Stromal Tumor (GIST);   Digestive System Disease;   Gastrointestinal Diseases;   Metastatic Cancer Intervention:   Drug: IDRX-42 Sponsor:   IDRx, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 5, 2022 Category: Research Source Type: clinical trials

A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors
Conditions:   Gastrointestinal Stromal Tumors;   Unresectable Solid Tumor;   Recurrent Metastatic Malignant Neoplasm Intervention:   Sponsors:   Xinhua Zhang, MD;   Beijing Cancer Hospital;   Fudan University;   Peking University People's Hospital;   Chinese PLA General Hospital;   Xiangya Hospital of Central South University;   Peking University Shenzhen Hospital;   Nanfang Hospital of Southern Medical Uni versity;   West China Hospital;   Jiangsu Cancer Institute & Hospital;   Shanghai Zhongshan Hospital;   Sun Yat-sen University;   Xijing Hospital;   Shengjing...
Source: ClinicalTrials.gov - July 19, 2022 Category: Research Source Type: clinical trials